- Home
- SPE vs CHRS Comparison
SPE vs CHRS Comparison
Compare SPE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPE
- CHRS
- Stock Information
- Founded
- SPE 1993
- CHRS 2010
- Country
- SPE United States
- CHRS United States
- Employees
- SPE N/A
- CHRS N/A
- Industry
- SPE Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPE Finance
- CHRS Health Care
- Exchange
- SPE Nasdaq
- CHRS Nasdaq
- Market Cap
- SPE 162.3M
- CHRS 94.0M
- IPO Year
- SPE N/A
- CHRS 2014
- Fundamental
- Price
- SPE $15.08
- CHRS $0.81
- Analyst Decision
- SPE
- CHRS Strong Buy
- Analyst Count
- SPE 0
- CHRS 4
- Target Price
- SPE N/A
- CHRS $5.38
- AVG Volume (30 Days)
- SPE 25.4K
- CHRS 2.1M
- Earning Date
- SPE 01-01-0001
- CHRS 05-08-2025
- Dividend Yield
- SPE 8.55%
- CHRS N/A
- EPS Growth
- SPE N/A
- CHRS N/A
- EPS
- SPE N/A
- CHRS 0.25
- Revenue
- SPE N/A
- CHRS $266,959,999.00
- Revenue This Year
- SPE N/A
- CHRS N/A
- Revenue Next Year
- SPE N/A
- CHRS $9.02
- P/E Ratio
- SPE N/A
- CHRS $3.24
- Revenue Growth
- SPE N/A
- CHRS 3.78
- 52 Week Low
- SPE $10.26
- CHRS $0.66
- 52 Week High
- SPE $12.59
- CHRS $2.61
- Technical
- Relative Strength Index (RSI)
- SPE 47.86
- CHRS 33.61
- Support Level
- SPE $14.72
- CHRS $0.89
- Resistance Level
- SPE $15.31
- CHRS $1.07
- Average True Range (ATR)
- SPE 0.19
- CHRS 0.08
- MACD
- SPE 0.01
- CHRS -0.01
- Stochastic Oscillator
- SPE 57.63
- CHRS 6.10
About SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is the United States based closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.